IL-28B/IFN-λ3 Recombinant Rabbit mAb (SDT-1838-120)
IL-28B/IFN-λ3 Recombinant Rabbit mAb (SDT-1838-120)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | IL-28B/IFN-λ3 |
| Immunogen | Recombinant Protein |
| Clone Number | SDT-1838-120 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | No cross-reactivity against IL-28A, IL-29, IL-10 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
IL28B is a newly-discovered type III interferon, with antiviral, antiproliferative, and immunomodulatory functions. Type III IFNs share homology with IL-10 and the IL-10R2 receptor subunit, leading to the speculation that these cytokines might be evolutionarily related. It was recently found that polymorphisms in IFN-lambda-4 (another type III interferon) are associated with circulating IL28B, and higher plasma IL28B are associated with higher production of antibodies to HBV surface antigen. IL28B is associated with the extent of lupus activity, in particular with active serosal and cutaneous disease. Combined treatment with IL28B and sorafenib (a small molecule multikinase inhibitor) facilitates a synergistic effect on suppressing hepatocellular carcinoma cancer growth and promoting cell apoptosis in vitro and in vivo.
Picture
Picture
Paired Recommendations
